Hemorragia cerebral asociada al activador plasminógeno cerebral en el ictus isquémico agudo en pacientes suramericanos

Autores/as

DOI:

https://doi.org/10.55717/XZDK2938

Palabras clave:

accidente cerebrovascular , trombólisis intravenosa , hemorragia cerebral

Resumen

El ictus isquémico tiene mal pronóstico y la transformación hemorrágica tras la trombólisis intravenosa puede aumentar la morbimortalidad. El presente estudio tuvo por objetivo investigar los principales factores asociados al desarrollo de hemorragia cerebral en el contexto de trombólisis farmacológica en una cohorte latinoamericana, en una unidad de cuidados neurocríticos. Se realizó un análisis retrospectivo de los factores de riesgo relacionados y reclutados. El análisis estadístico se realizó mediante ANOVA para las variables cuantitativas, y chi-cuadrado para las variables cualitativas. Se estudiaron 52 pacientes con accidente cerebrovascular isquémico agudo, tratados con activador del plasminógeno de tipo tisular recombinante (rt-PA) dentro de las 4.5 h posteriores al inicio de los síntomas. Los resultados mostraron que, la edad ≥ 70 años, el tabaquismo, la fibrilación auricular, la puntuación NIHSS antes de la trombólisis ≥ 20 y la presión sistólica al ingreso y a las 2 h después de la trombólisis (mmHg) ≥ 160 aumentaron los riesgos de transformación hemorrágica, después de la administración de rt-PA. Conclusiones: una mejor caracterización de los pacientes permitirá dirigir estrategias poblacionales en estas cohortes de forma más individualizada, para así reducir la morbimortalidad de estos pacientes, estratificándolos adecuadamente acorde a sus características.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Alamowitch, S., Turc, G., Palaiodimou, L., Bivard, A., Cameron, A., De Marchis, G. M., Fromm, A., Kõrv, J., Roaldsen, M. B., Katsanos, A. H., & Tsivgoulis, G. (2023). European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. European Stroke Journal, 8(1), 8–54. https://doi.org/10.1177/23969873221150022

Bagoly, Z., Szegedi, I., Kálmándi, R., Tóth, N. K., & Csiba, L. (2019). Markers of coagulation and fibrinolysis predicting the outcome of acute ischemic stroke thrombolysis treatment: A review of the literature. Frontiers in Neurology, 10, 513. https://doi.org/10.3389/fneur.2019.00513

Berge, E., Whiteley, W., Audebert, H., De Marchis, G. M., Fonseca, A. C., Padiglioni, C., de la Ossa, N. P., Strbian, D., Tsivgoulis, G., & Turc, G. (2021). European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. European Stroke Journal, 6(1), I–LXII. https://doi.org/10.1177/2396987321989865

Botelho, A., Rios, J., Fidalgo, A. P., Ferreira, E., & Nzwalo, H. (2022). Organizational factors determining access to reperfusion therapies in ischemic stroke-systematic literature review. International Journal of Environmental Research and Public Health, 19(23). https://doi.org/10.3390/ijerph192316357

Charbonnier, G., Bonnet, L., Biondi, A., & Moulin, T. (2020). Intracranial bleeding after reperfusion therapy in acute ischemic stroke. Frontiers in Neurology, 11, 629920. https://doi.org/10.3389/fneur.2020.629920

Evans, N. R., Sibson, L., Day, D. J., Agarwal, S., Shekhar, R., & Warburton, E. A. (2022). Hyperacute stroke thrombolysis via telemedicine: a multicentre study of performance, safety and clinical efficacy. BMJ Open, 12(1), e057372. https://doi.org/10.1136/bmjopen-2021-057372

Fu, Q., Wang, X., Zhang, D., Shi, L., Wang, W., Guo, Z., Shan, P., Chen, G., & Feng, Z. (2022). Improving thrombolysis for acute ischemic stroke: The implementation and evaluation of a theory-based resource integration project in China. International Journal of Integrated Care, 22(1), 9. https://doi.org/10.5334/ijic.5616

Han, T. S., Gulli, G., Fry, C. H., Affley, B., Robin, J., Fluck, D., Kakar, P., & Sharma, P. (2022). Adverse consequences of immediate thrombolysis-related complications: a multi-centre registry-based cohort study of acute stroke. Journal of Thrombosis and Thrombolysis, 53(1), 218–227. https://doi.org/10.1007/s11239-021-02523-2

Herath, H. M. M. T. B., Rodrigo, C., Alahakoon, A. M. B. D., Ambawatte, S. B., Senanayake, S., Senanayake, B., & Fernando, A. (2021). Outcomes of stroke patients undergoing thrombolysis in Sri Lanka; an observational prospective study from a low-middle income country. BMC Neurology, 21(1), 434. https://doi.org/10.1186/s12883-021-02475-3

Koga, M., Yamamoto, H., Inoue, M., Asakura, K., Aoki, J., Hamasaki, T., Kanzawa, T., Kondo, R., Ohtaki, M., Itabashi, R., Kamiyama, K., Iwama, T., Nakase, T., Yakushiji, Y., Igarashi, S., Nagakane, Y., Takizawa, S., Okada, Y., Doijiri, R., … THAWS Trial Investigators. (2020). Thrombolysis with alteplase at 0.6 mg/kg for stroke with unknown time of onset: A randomized controlled trial: A randomized controlled trial. Stroke, a Journal of Cerebral Circulation, 51(5), 1530–1538. https://doi.org/10.1161/STROKEAHA.119.028127

Lin, S.-F., Chen, C.-F., Hu, H.-H., Ho, B.-L., Chen, C.-H., Chan, L., Lin, H.-J., Sun, Y., Lin, Y.-Y., Chen, P.-L., Lin, S.-K., Wei, C.-Y., Lin, Y.-T., Lee, J.-T., Chao, A.-C., & Taiwan Thrombolytic Therapy for Acute Ischemic Stroke Study Group *. (2022). Comparison of different dosages of alteplase in atrial fibrillation-related acute ischemic stroke after intravenous thrombolysis: A nationwide, multicenter, prospective cohort study in Taiwan. Journal of the American Heart Association, 11(3), e023032. https://doi.org/10.1161/JAHA.121.023032

Modrego, P. J. (2019). The risk of symptomatic intracranial hemorrhage after thrombolysis for acute stroke: Current concepts and perspectives. Annals of Indian Academy of Neurology, 22(3), 336–340. https://doi.org/10.4103/aian.AIAN_323_18

Ng, S. H.-X., Wong, A. W. K., Chen, C. H., Tan, C. S., Müller-Riemenschneider, F., Chan, B. P. L., Baum, M. C., Lee, J.-M., Venketasubramanian, N., & Koh, G. C.-H. (2019). Stroke factors associated with thrombolysis use in hospitals in Singapore and US: A cross-registry comparative study. Cerebrovascular Diseases (Basel, Switzerland), 47(5–6), 291–298. https://doi.org/10.1159/000502278

Nordanstig, A., Curtze, S., Gensicke, H., Zinkstok, S. M., Erdur, H., Karlsson, C., Karlsson, J.-E., Martinez-Majander, N., Sibolt, G., Lyrer, P., Traenka, C., Baharoglu, M. I., Scheitz, J. F., Bricout, N., Hénon, H., Leys, D., Eskandari, A., Michel, P., Hametner, C., … EVA-TRISP Investigators. (2021). EndoVAscular treatment and ThRombolysis for Ischemic Stroke Patients (EVA-TRISP) registry: basis and methodology of a pan-European prospective ischaemic stroke revascularisation treatment registry. BMJ Open, 11(8), e042211. https://doi.org/10.1136/bmjopen-2020-042211

Rotimi, O. R., Ajani, I. F., Penwell, A., Lari, S., Walker, B., & Nathaniel, T. I. (2020). In acute ischemic stroke patients with smoking incidence, are more women than men more likely to be included or excluded from thrombolysis therapy? Women’s Health (London, England), 16, 1745506520922760. https://doi.org/10.1177/1745506520922760

Sandset, E. C., Anderson, C. S., Bath, P. M., Christensen, H., Fischer, U., Gąsecki, D., Lal, A., Manning, L. S., Sacco, S., Steiner, T., & Tsivgoulis, G. (2021). European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. European Stroke Journal, 6(2), XLVIII–LXXXIX. https://doi.org/10.1177/23969873211012133

Sykora, M., Kellert, L., Michel, P., Eskandari, A., Feil, K., Rémi, J., Ferrari, J., Krebs, S., Lang, W., Serles, W., Siarnik, P., Turcani, P., Kovacik, M., Bender, B., Mengel, A., Poli, K., & Poli, S. (2020). Thrombolysis in Stroke with Unknown Onset Based on non-Contrast Computerized Tomography (TRUST CT). Journal of the American Heart Association, 9(4), e014265. https://doi.org/10.1161/JAHA.119.014265

Toyoda, K., Koga, M., Iguchi, Y., Itabashi, R., Inoue, M., Okada, Y., Ogasawara, K., Tsujino, A., Hasegawa, Y., Hatano, T., Yamagami, H., Iwama, T., Shiokawa, Y., Terayama, Y., & Minematsu, K. (2019). Guidelines for intravenous thrombolysis (recombinant tissue-type plasminogen activator), the third edition, march 2019: A guideline from the japan stroke society. Neurologic Medico-Chirurgical, 59(12), 449–491. https://doi.org/10.2176/nmc.st.2019-0177

Tsivgoulis, G., Kargiotis, O., De Marchis, G., Kohrmann, M., Sandset, E. C., Karapanayiotides, T., de Sousa, D. A., Sarraj, A., Safouris, A., Psychogios, K., Vadikolias, K., Leys, D., Schellinger, P. D., & Alexandrov, A. V. (2021). Off-label use of intravenous thrombolysis for acute ischemic stroke: a critical appraisal of randomized and real-world evidence. Therapeutic Advances in Neurological Disorders, 14, 1756286421997368. https://doi.org/10.1177/1756286421997368

Zhou, Y., Yan, S., Song, X., Gong, Y., Li, W., Wang, M., Yin, X., Hu, B., & Lu, Z. (2019). Intravenous thrombolytic therapy for acute ischemic stroke in Hubei, China: a survey of thrombolysis rate and barriers. BMC Neurology, 19(1), 202. https://doi.org/10.1186/s12883-019-1418-z

Descargas

Publicado

29-09-2023

Métricas

Cómo citar

Theran León, J. S., Dulcey Sarmiento, L. A., Gómez Ayala, J. A., Cabrera Peña, V., Parales Strauch, R. G., Blanco Pimiento, E. C., Ciliberti Artavia, M. P., Martínez, J. C., Mayorca, J. C., & Cala, M. A. (2023). Hemorragia cerebral asociada al activador plasminógeno cerebral en el ictus isquémico agudo en pacientes suramericanos. Revista Salud Y Desarrollo, 7(2), e606. https://doi.org/10.55717/XZDK2938

Número

Sección

Artículos originales

Artículos más leídos del mismo autor/a